MxT Biotech

MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology.

The Hydroporator™ is a non-viral microfluidic platform for highly effective delivery of external cargos such as plasmid DNA, mRNA, proteins, CRISPR-Cas9 RNPs, and nanoparticles into primary cells. The Hydroporator™ technology enables high delivery efficiency, easy operation, low cost, high scalability, minimal cell perturbation (i.e., preserved cell function and viability), and cell type/cargo insensitive delivery. The platform is said to be free from the challenges from viral transduction, lipofection and electroporation, establishing a new avenue to accelerate cancer immunotherapy, cellular engineering and genome editing.

MXT Biotech was founded in March 2021 by Professor Aram Jung of Korea University. In May 2022, Mxt raised KRW ₩5 billion (~USD $4M) in a Series A funding from BNK Venture Capital, DAYLI Partners, Hyundai Investment Partners, We Ventures Partners, and AJU IB Investment.

Subscribe for alerts on new companies featured on Startups.Bio

Vilya
Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class …
VentureRadar’s Top 100 Emerging Biotech Start-ups Report
Biotechnology is in the midst of a exciting era of innovation, with an ever-expanding toolbox of modalities and approaches spawning development of exciting new vaccines, medicines and therapies. VentureRadar's Top …
CorriXR Therapeutics
CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology. CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not …
THERAtRAME
THERAtRAME was founded based on new insights in transfer RNA (tRNA) epitranscriptomics resulting from over a decade of fundamental research at the GIGA Institute (ULiège) and WELBIO. Transfer RNAs mediate …

View all recently featured startups

Tags: